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There has been a resurgence of interest in the devel-
opment of androgen receptor (AR) inhibitors with
alternative modes of action to overcome the devel-
opment of resistance to current therapies. We
demonstrated previously that one promising strat-
egy for combatting mutation-driven drug resistance
is to target the Binding Function 3 (BF3) pocket of
the receptor. Here we report the development of a
potent BF3 inhibitor, 3-(2,3-dihydro-1H-indol-2-yl)-
1H-indole, which demonstrates excellent antiandro-
gen potency and anti-PSA activity and abrogates
the androgen-induced proliferation of androgen-
sensitive (LNCaP) and enzalutamide-resistant
(MR49F) PCa cell lines. Moreover, this compound
effectively reduces the expression of AR-dependent
genes in PCa cells and effectively inhibits tumor
growth in vivo in both LNCaP and MR49F xenograft
models. These findings provide evidence that target-
ing the AR BF3 pocket represents a viable therapeu-
tic approach to treat patients with advanced and/or
resistant prostate cancer.
INTRODUCTION
The human androgen receptor (AR), a member of the nuclear
hormone receptor (NHR) family, is a ligand-dependent transcrip-
tion factor with known significant therapeutic relevance in pros-
tate cancer (PCa) (Denmeade and Isaacs, 2002). All conventional
AR-directed therapeutics, including the most potent new clini-
cally approved antiandrogen, enzalutamide, targets the hor-
mone binding pocket of the receptor (Clegg et al., 2012; Tran
et al., 2009). However, over prolonged periods of treatment,
the therapeutic efficacy of these drugs declines because of
the development of resistance (Adamo et al., 2012; Lassi and
Dawson, 2009). Numerous factors are causative for this phe-
nomenon, including mutations in the ligand binding pocket of1476 Chemistry & Biology 21, 1476–1485, November 20, 2014 ª2014the AR, resulting in structural changes in the receptor, allowing
it to regain agonist conformation. These events weaken pro-
tein-drug interactions and allow antiandrogens to promote the
recruitment of coactivators by the AR, enhancing its transcrip-
tional activity (Miyamoto et al., 1998). Therefore, there is an
urgent need to develop new types of anti-AR therapeutics that
exhibit entirely different modes of AR inhibition. For instance,
rather than blocking androgen binding to the AR, such new drugs
could target regulatory sites on the receptor and prevent coacti-
vator recruitment directly.
Protein-protein interaction sites on NHRs are essential for their
nuclear translocation and transcriptional activity. For example,
the Binding Function 3 (BF3) site on the surface of the AR regu-
lates transcriptional activity by recruiting coregulators such as
FKBP52 (De Leon et al., 2011) and Bag-1L (Jehle et al., 2014).
It is also engaged in crosstalk with the adjacent Activation
Function 2 site (Grosdidier et al., 2012). Therapeutic targeting
of the AR BF3 provides an opportunity to develop AR inhibitors
with alternative mechanisms of action and the potential to
circumvent resistance to conventional antiandrogens. In this
context, AR inhibitors directed toward the BF3 site could afford
additional and/or complementary lines of therapy for patients
with advanced and treatment-resistant disease.
One possible strategy for inhibiting protein-protein interaction
sites is the development of short peptides or peptidomimetics,
which mimic binding features of critical amino acids on the pro-
tein surface (Gunther et al., 2009; Parent et al., 2008). However,
because of limitations in potency, molecular size, synthetic
feasibility, low specificity, and/or poor pharmacokinetic charac-
teristics of peptides and their mimetics (Mullard, 2012), such
inhibitors have not yet been clinically developed for NHRs. To
date, only a handful of such peptidomimetic products have
progressed to in vivo investigations or preclinical trials (Ravin-
dranathan et al., 2013).
Targeting protein-protein interactions with small molecules
also presents many challenges but is less associated with the
above limitations. Accordingly, we took advantage of available
atomic details derived from AR BF3 crystal structures and per-
formed systematic in silico screening of large libraries of avail-
able compounds from which we identified several promising
BF3 binding candidates (Lack et al., 2011). We previously solvedElsevier Ltd All rights reserved
Figure 1. Strategy Used to Obtain Highly Active AR BF3 Inhibitors
Cpd, compound.
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binders and validated the adequacy of our in silico screening
technique (Lack et al., 2011).
In this study, we selected the most potent, low-micromolar
AR BF3 inhibitors identified to date, 2-[(2-phenylethyl) sulfanyl]-
1H-1,3-benzodiazole (Munuganti et al., 2013), and used it as
a template for further drug optimization. Using a systematic
in silico screen, we selected and tested 23 promising candidates
bearing an indole scaffold. In vitro functional analysis confirmed
that some of these compounds exhibit anti-AR activity and
reduce prostate-specific antigen (PSA) levels to the nanomolar
range. Further in vivo evaluation of one of the identified com-
pounds, 3-(2,3-dihydro-1H-indol-2-yl)-1H-indole (compound
23), demonstrated a significant inhibition of cell proliferation
and tumor growth in lymph node carcinoma of the prostate
(LNCaP) human prostate cancer xenografts. Importantly, the
lead AR BF3 inhibitor also demonstrated an effective inhibition
of growth and serum PSA production in enzalutamide-resistant
xenograft tumors.
RESULTS
Identification of a Potent Chemical Series
by a Shape-Based Similarity Search
In previous studies, our group reported the identification of
several 2-((2-phenoxyethyl) thio)-1H-benzo[d]imidazole deriva-
tives that specifically bind to the AR BF3 site (Munuganti et al.,
2013). In that investigation, we synthesized a series of com-
pounds by substituting different functional groups on imid-
azole/indole and benzene moieties, which resulted in their
increased anti-AR potency. However, synthetic derivatives
with longer linker fragments connecting the aromatic systems
did not generally demonstrate improved activity (with the excep-
tion of compound 1). In this study, we searched for chemicals
containing various shorter linkers using compound 1 as
template. Instant JChem, a 2D similarity search tool from
ChemAxon, was employed to search for structural analogs of
2-[(2-phenylethyl)sulfanyl]-1H-1,3-benzodiazole (compound 1).
A similarity search was performed against the ZINC database
v12.0 containing 18 million compounds (Irwin et al., 2012). All
software parameters were set to their default values. The search
resulted in ten candidate structures. The identified compounds
were mapped to the query template and ranked according to
generated ‘‘Tanimoto coefficient (Tc)’’ values,
Tc=
A
A+B C;
where A and B are the number of features present in compounds
A and B, respectively, and C is the number of features shared
by A andB. Hence, Tc quantifies the fraction of features common
to A and B to the total number of features of A or B, where the
C term in the denominator corrects for double-counting of the
features.
The identified molecules were inspected visually, and only
compound 2 was selected because it contains a short linker
that connects two aromatic systems and obtained a Tc value
above 0.8. Because compound 2 represented chemotype,3-
[(E)-2-phenylethenyl]-1H-indole, it was used as a template for
another similarity search and led to the identification of a seriesChemistry & Biology 21, 1476–148of N-[1H-indol-3-yl-methylidene] aniline derivatives, compounds
3–11. In the same way, each subsequent chemical series
(3-[(E)-2-phenyldiazen-1-yl]-1H-indole, compounds 12–18; 3-
(3H-indol-2-yl)-1H-indole, compounds 19–22; and 3-(2,3-dihy-
dro-1H-indol-2-yl)-1H-indole, compounds 23 and 24) was
identified based on the scaffold of active compounds from
the previous search (compounds 2, 3, 13, and 19), as shown
in Figure 1. Therefore, from each similarity search step, we ob-
tained a different number of hits, totaling 295 identified chemical
structures. These compounds were further evaluated using our
established in silico pipeline as discussed below.
Molecular Docking of Selected Compounds
into the AR BF3 Pocket
The BF3 site represents a hydrophobic groove located adjacent
to the activation function 2 (AF2) pocket on the surface of the
AR. Being a protein-protein interaction site, BF3 represents a
challenging target. Nevertheless, it offers an attractive option
for direct inhibition of the AR transactivation.
Using our in-house computational drug discovery pipeline,
we virtually tested the selected 295 compounds. Our in silico5, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1477
Figure 2. Unrooted Phylogenetic Tree Representing the Structural
Diversity of Reported BF3 Inhibitors Compared with Published BF3
Inhibitors and AR Drugs
The tree is built based on pairwise Tanimoto distances between Daylight
fingerprints of 44 AR inhibitors, including four commercial antiandrogens
(S17-S20) and 17 published BF3 inhibitors (S1-S16). Only the highest active
inhibitor from each colored cluster is depicted.
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consensus voting procedures (see Experimental Procedures
for more details). Initially, all molecules were docked into the
AR crystal structure (Protein Data Bank [PDB] ID code 4HLW,
2.5 A˚ resolution) using the Glide SP program (Friesner et al.,
2004). Our previous studies indicated that charged amino acids
Glu837 and Leu830 form anH-bond interaction and hydrophobic
contacts with BF3 binders and are critical for protein-ligand
coordination. Therefore, we applied the corresponding H-bond
and hydrophobic constraints during the docking. Compounds
that received a moderate to high score by Glide SP were
selected and redocked into the 4HLW structure using the eHiTS
docking protocol (Zsoldos et al., 2007). To improve the accuracy
of the predicted binding orientation, the root-mean-square devi-
ation (rmsd) was calculated for the docking poses generated
by the Glide and eHiTS programs. Only molecules with docking
poses with rmsd < 2.0 A˚ were subjected to further analysis.
At the next step, the selected ligands underwent additional
on-site rescoring using the Ligand Explorer (LigX) program and
the pKi predicting module of the Molecular Operating Environ-
ment (MOE) (Chemical Computing Group). With this information,
a cumulative scoring of four different predicted parameters
(Glide score, eHiTS score, rmsd, LigX score, and pKi predicted
by the MOE) was computed, with each molecule receiving
a binary 1.0 score for every ‘‘top 20% appearance.’’ The final
cumulative vote allowed for selecting 70 molecules associated
with a higher probability of being BF3 binders. These com-
pounds were then visually inspected, and 23 chemicals
(compounds 2–24; Figure 1) were selected.
To ensure that these compounds represent an entirely
different chemical class of AR inhibitors, we compared them
with previously reported BF3 binders (Este´banez-Perpin˜a´ et al.,1478 Chemistry & Biology 21, 1476–1485, November 20, 2014 ª20142007; Lack et al., 2011; Munuganti et al., 2013) (S1–S16;
Table S1 available online) and with known antiandrogens (S17–
S20; Table S1) on the basis of structural and physicochemical
similarity. The assembled set was clustered according to pair-
wise Tanimoto distances and using Daylight fingerprints. A clus-
tering threshold of 0.5 resulted in 17 groups, highlighting the
structural diversity of the set (Figure 2). In addition, these struc-
tures were clustered according to their physicochemical similar-
ity (Figure S1). The heat map highlights the distances calculated
in the first three principal component spaces (variance explained
>95%) that originated from nine drug likeness descriptors (polar
surface area, logP, logS, molecular weight, number of H-bond
donors, H-bond acceptors, heavy atoms, rings, and rotatable
bonds). From the resulting phylogenetic tree and the heat map,
one can see that the identified chemicals are quite distinct
from the previously reported BF3 binders and from conventional
antiandrogens listed in Table S1. Hence, these 23 chemicals
were purchased and further investigated experimentally.
Cell-Based Testing and In Vitro Characterization
All purchased compounds were screened for their ability to
inhibit AR transcriptional activity using a nondestructive, cell-
based, enhanced GFP (eGFP) AR transcriptional assay (Tavas-
soli et al., 2007) (see Experimental Procedures). In this system,
the expression of eGFP is under the direct control of an
androgen-responsive probasin-derived promoter and enables
the quantification of AR transcriptional activity. Because all
compounds exhibited >75% inhibition of AR transcription at
the screening concentration of 3 mM, they were all subjected to
concentration-dependent titration, along with enzalutamide as
a positive control. We established an inhibitory concentration,
50% (IC50) value for enzalutamide of 0.08 mM, whereas the
tested compounds exhibited IC50 values in the range of 0.3–
25 mM (Figure 1).
In addition, we tested the most active derivatives (compounds
12, 13, 19, and 23) with SRC2 peptide and androgen displace-
ment assays to check whether they displace the activator pep-
tide from the AF2 site and androgen from the ligand binding
pocket. None of the tested molecules showed any significant
activity in these assays at the concentrations measured, con-
firming that they likely target the BF3 pocket (see Figure S2).
Furthermore, biolayer interferometry (BLI) studies demonstrated
a direct, reversible, and dose-dependent interaction between
these compounds and the AR ligand binding domain (LBD). Fig-
ures 3A and 3B feature the eGFP IC50 curve and BLI graph for the
highest active compound, 23. Figure S3 shows AR eGFP dose-
response curves and BLI graphs for compounds 12, 13, and 19.
To confirm compound 23’s binding to the BF3 pocket, a muta-
genesis study was performed. Preliminary results with mutants
F673E, E837A, and N833W confirmed that compound 23 did
not show any binding to the protein compared with the wild-
type in a BLI assay (Figure S4). Because these residues are
critical for protein-ligand interactions, compound 23 binding
has been abolished upon mutating them.
Compound 23 Significantly Reduces PSA Expression
in LNCaP and Enzalutamide-Resistant Cells
To further validate compound 23 as an AR inhibitor, we tested its
activity by quantifying its effect on the production of endogenousElsevier Ltd All rights reserved
Figure 3. Activity Profile of Compound 23
(A) Dose-response curve illustrating the inhibiting
effect of compound 23 (IC50 = 0.31 mM) and
enzalutamide (IC50 = 0.08 mM) on the AR tran-
scriptional activity in LNCaP cells. Data points
represent the mean of two independent experi-
ments performed in triplicate. Error bars represent
the SEM for n = 6 values. Data were fitted using log
of concentration (conc) of the inhibitors versus
percent activation with GraphPad Prism 6.
(B) BLI dose-response curves (3–100 mM) reflect-
ing the direct binding of compound 23.
(C) The effect of compound 23 (IC50 = 0.21 mM) in
comparison with enzalutamide on PSA (IC50 =
0.09 mM) in a dose-response manner in LNCaP
cells.
(D) The effect of compound 23 in comparison with
enzalutamide on PSA (IC50 = 6.02 mM) in a dose-
response manner in enzalutamide-resistant cells
(MR49F).
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serine protease and is widely used as a biomarker for PCa. As
expected, compound 23 induced a significant decrease in
secreted PSA levels in LNCaP cells, with the corresponding
IC50 value established at 0.21 mM (Figure 3C). Compound 23
was further evaluated in the enzalutamide-resistant PCa cell
line MR49F (Kuruma et al., 2013). As anticipated, enzalutamide
was confirmed to be ineffective against MR49F cells, whereas
compound 23 caused a significant reduction in the PSA ex-
pressed in MR49F cells (IC50 = 6.02 mM; see Figure 3D). These
results provided additional assurance regarding the effective-
ness of our lead BF3 inhibitor and its applicability for targeting
enzalutamide-resistant PCa cells.
Compound 23 Displaces Bag-1L Peptide from the AR
BF3 Pocket
Recently, Jehle et al. (2014) reported that Bag-1L protein inter-
acts with the AR BF3 pocket through its hexapeptide repeat
sequence, GARRPR. We anticipated that the binding of our
lead inhibitor to the BF3 target should disrupt the interaction
between the GARRPRmotif and the AR. Therefore, the displace-
ment of the bound peptide from the AR could provide another
direct validation for the lead compound, 23. Accordingly, we
tested compound 23 in the fluorescence polarization assay as
described by Jehle et al. (2014). We found that compound 23
blocked the interaction of Bag-1L peptide with the AR with a
corresponding IC50 value of 6.10 mM, whereas compound 22,
characterized in prior experiments as non-AR-disrupting and,
hence, used as a negative control, exhibited no effect on peptide
displacement (Figure 4A). Interestingly, Casodex also demon-
strated a moderate displacement of Bag-1L from the BF3
pocket. This could be explained by Casodex binding to the
androgen binding pocket of the AR, which then destabilizes
the protein and allosterically affects the BF3. When Casodex
was tested with AR-T877A mutant protein (where the drugChemistry & Biology 21, 1476–1485, November 20, 2014 ªacts as an agonist and stabilizes the
AR), it did not displace Bag-1L peptide,
whereas compound 23 exhibited anunchanged potency against the mutant AR-T877A (IC50 value
of 7.51 mM; Figure S5). Collectively, this implies that compound
23 binds directly to the AR BF3 site.
Compound 23 Potently Inhibits Androgen-Stimulated
Proliferation of LNCaP and Enzalutamide-Resistant
PCa Cells
To determine the efficacy of compound 23 on the viability of
various PCa cell lines, its activity was assessed in LNCaP,
MR49F, and PC3 cells. An 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay
was performed after 4 days of treatment with compound 23 in
a dose-dependent manner. Figure 4B shows that compound
23 is very effective in inhibiting the growth of both LNCaP and
enzalutamide-resistant cells, achieving IC50 values of 0.71 and
2.01 mM, respectively. Moreover, compound 23 did not show
any effect on AR-independent PC3 cells, confirming its AR-spe-
cific activity.
Compound 23 Reduces the Expression of AR
Target Genes
Using a chemical genomic approach (Bredel and Jacoby, 2004),
the transcriptional responses of PCa cells to compound 23
and enzalutamide (positive control) were investigated using
Agilent gene expression microarrays. The dosage for compound
23 and enzalutamide used in the microarray experiments was
determined based on the corresponding IC50(PSA) and IC90(PSA)
concentrations. Thus, compound 23 was administered at 0.20
and 1.50 mM, respectively, and enzalutamide was used at con-
centrations of 0.10 and 0.30 mM. For themicroarray experiments,
LNCaP cells were grown in the presence of 0.1 nM R1881 for
24 hr. The use of IC50 and inhibitory concentration, 90% (IC90)
concentrations enabled us to study the effect of the compounds
on overall gene expression and explore any possible toxicity. Fig-
ure 5A highlights gene expression changes established for two2014 Elsevier Ltd All rights reserved 1479
Figure 5. Chemogenomic Analysis of Compound 23 and Enzaluta-
mide
(A) Gene expression of PSA (KLK3), TMPRSS2, and actin (ACTB) of cells
treated with the five conditions. The gene expression level is shown as per-
centages of the vehicle control (DMSO). * indicates a significant raw p value
(<0.05) based on two-sample t tests between the experimental condition and
control.
(B) Overlaps of differentially expressed genes between two groups: compound
23 (IC90) versus vehicle and enzalutamide (IC90) versus vehicle. The italicized
numbers indicate upregulation, whereas bold numbers indicate down-
regulation.
Figure 4. Peptide Displacement Profile and Antiproliferative Effect
of Compound 23
(A) Fluorescence polarization experiment showing competition between
fluorescein isothiocyanate (FITC)-labeled Bag-1L (61–80) peptide (12.5 nM)
and serially diluted Casodex, compound 23, compound 22, and unlabeled
core GARRPR hexapeptide (100–0.05 mM) for binding to AR-LBD (2 mM). The
competition experiments were performed at conditions for maximum polari-
zation of FITC-labeled peptide and AR-LBD.
(B) The effect of compound 23 on cell viability in LNCaP, an enzalutamide-
resistant cell line (MR49F), and PC3 cells. Percent cell viability is plotted in a
dose-dependent manner. Data are presented as mean ± SEM. p < 0.05 was
considered a very significant effect (*) on LNCaP and MR49F compared with
PC3 cells. Compound 23 showed IC50 values of 0.71 and 2.01 mM in LNCaP
and MR49F cells, respectively.
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In the presence of either compound 23 or enzalutamide (both
administered at IC50 concentrations), gene expression was
reduced to 50%60% of the original level (vehicle-treated).
Increasing the concentration of both compounds to IC90 dosage
further reduced gene expression to 40% of the original magni-
tude. Both compounds showed no effect on the expression of
actin (ACTB), used as a negative control.
To identify other genes affected by compound 23, the
following criteria were applied to 50,737 transcripts measured
on the Agilent arrays: adjusted p value < 0.05 after two-sample
t tests andmultiple testing corrections (Benjamini andHochberg,
1995) and fold change% 0.5 orR 2. A total of 52 genes demon-
strated at least a 2-fold increase (n = 11) or 2-fold decrease (n =
41) of expression in response to the treatment compared with
vehicle (results are shown in Figure 5B and Table S2). In the
case of treatment with enzalutamide (IC90), 41 genes demon-
strated more than a 2-fold increase (n = 9) or 2-fold decrease
(n = 32) in expression (Table S3). As illustrated in Figure 5B,
two genes were upregulated and 18 genes were downregulated
by both compound 23 and enzalutamide.1480 Chemistry & Biology 21, 1476–1485, November 20, 2014 ª2014To explore any potential toxic effects of the two chemicals,
differentially expressed genes were examined for any overlap
against a previously published genotoxic gene set consisting
of 48 genes, the expression of which changed upon treatment
of genotoxicants (Ellinger-Ziegelbauer et al., 2009). None of the
differentially expressed genes overlapped with the genotoxic
gene set.
Selectivity of Compound 23
The selectivity of a compound 23 toward other nuclear receptors
was evaluated using the commercial SELECT screen provided
by Life Technologies (see Supplemental Experimental Proce-
dures). Figure S6 shows that compound 23 does not have a
significant effect on the glucocorticoid receptor (GR) or the
estrogen receptor-a (ERa). The compound demonstrated an
80- to 100-fold decrease in inhibitor activity against ERa
(IC50 = 22 mM) and GR (IC50 = 30 mM) compared with the AR
(IC50 = 0.31 mM). As anticipated, compound 23 demonstrated
a somewhat better, although 7-fold weaker, activity (IC50 =
2.1 mM) against the progesterone receptor (PR) because the
AR and PR are more similar in their sequences in the BF3 regionElsevier Ltd All rights reserved
Figure 6. The in Vivo Effect of Compound 23 in LNCaP and Enzalutamide-Resistant Xenograft Models
(A) The in vivo effect of compound 23 on the tumor volume of the LNCaP mice xenograft. Data are presented as mean ± SEM. A p value < 0.01 was considered
very significant (*) compared with the vehicle control.
(B) The in vivo effect of compound 23 on PSA level of LNCaPmice xenograft. Data are presented asmean ± SEM. A p value < 0.01 was considered very significant
(*), and a p value < 0.001 was considered extremely significant (**) compared with the vehicle control.
(C) The in vivo effect of compound 23 on the tumor volume of the MR49F mice xenograft. Data are presented as mean ± SEM. A p value < 0.05 was considered
significant (*) compared with the vehicle control.
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tion between the AR, GR, and ERa.
Compound 23 Inhibits AR-Dependent Growth
of Xenograft Tumors In Vivo
The in vivo effect of compound 23 was evaluated with both
androgen-sensitive LNCaP and enzalutamide-resistant MR49F
xenografts. The pharmacokinetic analysis of compound 23 and
its metabolites following intravenous (i.v.), oral (PO), or intraper-
itoneal (i.p.) administration demonstrated a moderate metabolic
stability of compound 23,with three glucuronides established as
primary biotransformation products. The hydroxylation products
were observed in lesser amounts. The i.v., PO, and i.p. serum
profiles of compound 23 suggest that it could be administered
orally with substantial retention up to 24 hr. For i.v., PO, and
i.p., respectively, the maximum plasma drug concentration
was established at approximately 400, 150, and 12 mM, and
half-life was estimated as 2.3, 2.3, and 3.4 hr, respectively.
Based on the initial in vitro data (AR eGFP IC50 = 0.31 mM), it
was expected that the plasma concentration of the drug should
remain within the predicted therapeutic window for at least 12 hrChemistry & Biology 21, 1476–148when delivered PO. Initial toxicity experiments (PO) demon-
strated no systemic toxicity, and doses up to and including
200 mg/kg twice a day could be tolerated by mice with no
decrease in body weight for 3 weeks.
A dose of 200 mg/kg administered twice a day was chosen
based on these preliminary studies. The in vivo screening for
tumor growth was initially done using the castration-resistant
tumor xenograft model (Cheng et al., 2006; Miyake et al., 2000;
Sato et al., 1996; Snoek et al., 2009) in castrated hosts (Kuruma
et al., 2013; Zhang et al., 2009). When tumor regrowth was
observed and the serum PSA was raised to precastration levels,
the mice were treated with compound 23 at 200 mg/kg. The
growth of the tumor volume was effectively suppressed in
this castration-resistant xenograft model with both LNCaP (p <
0.01, Figure 6A) andMR49F cells (p < 0.05, Figure 6C) compared
with the vehicle control. Moreover, compound 23 significantly
decreased the serum PSA levels in the LNCaP xenograft model
(p < 0.01, Figure 6B). However, there was no significant change
in the PSA levels of MR49F xenograft-bearing mice compared
with the vehicle-treated mice. These results clearly indicate
that compound 23 could effectively inhibit androgen-sensitive5, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1481
Figure 7. Predicted Binding Orientation of Compound 23 inside of
the BF3 Pocket
Black, hydrogen bonds; orange, hydrophobic residues; blue, positively
charged residues; red, negatively charged residues.
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that this class of AR inhibitors has the potential to yield an
AR-targeting drug that could also be useful in the treatment of
patients with enzalutamide-resistant tumors.
DISCUSSION
Androgen receptor signaling has been shown to regulate the
proliferation of PCa cells even in the advanced phase of the
disease. Progression to the castration-resistant state depends
on the AR (even after androgen deprivation therapy) because
the receptor functions through its mutated form and/or is over-
expressed (Chen et al., 2009). Therefore, the AR still remains a
key driver of castration-resistant prostate cancer. One of the
promising strategies to combat resistance is to design com-
pounds that target sites alternative to the androgen binding
site in the AR ligand binding domain, such as the BF3 site,
believed to function as a coregulatory site mediating coactivator
recruitment (De Leon et al., 2011; Este´banez-Perpin˜a´ et al.,
2007). The BF3 regulatory site of the AR offers a direction
for developing alternative AR-directed PCa therapeutics. By
harnessing the power of in silico modeling combined with ex-
perimental evaluations of efficacy, we previously discovered
a variety of BF3 binders that could effectively inhibit the AR
at micromolar concentrations. Even though these compounds
were effective in PCa cells in vitro, their potency was not suffi-
cient for in vivo studies. Therefore, this study was initiated to
develop a chemical series of BF3 inhibitors that would be potent
enough for evaluation in PCa human xenograft model and pro-
vide the foundation for subsequent therapeutic development.
At the start, a previously identified BF3 binder, compound 1,
was selected as the chemical template for a similarity search in
the chemical space of a full ZINC database. As a result, 295
chemicals were selected and subjected to docking in the AR
BF3 site. Based on our knowledge of BF3 residue-ligand inter-
actions, compounds that interact with Glu837 and Leu830
were selected, purchased, and evaluated in our AR eGFP assay
(Tavassoli et al., 2007). Figure 1 illustrates that some of the
selected chemicals, especially compound 23, demonstrate a
higher potency against the AR (IC50 = 0.31 mM) in our cellular1482 Chemistry & Biology 21, 1476–1485, November 20, 2014 ª2014transcription/reporter assay. Figure 3A shows that compound
23 exhibits dose-dependent inhibition of the AR (IC50 =
0.31 mM), and Figure 3B illustrates its direct binding to the AR
LBD. Figure 7 indicates that compound 23 has tight binding to
the AR BF3 pocket and forms a critical H-bond interaction with
its Glu837 residue and van der Waals contacts with Ile672,
Pro723, and Leu830. In addition, we calculated a ligand lipophi-
licity efficiency (LLE) score for all of the compounds reported
here (Table S4). Because cell permeability, absorption, micro-
somal clearance, and pharmacological clearance of the drugs
are associated with clogP, it has been suggested that LLE is a
critical factor to determine the quality of the lead candidates
(Leeson and Springthorpe, 2007). Compound 23 received a
high LLE score, giving confidence to the premise that this
chemical is a potential lead.
Based on these initial results, compound 23 was selected for
further evaluation. The activity of this AR inhibitor was further
confirmed by its ability to decrease endogenous PSA levels in
PCa cells (Figure 3). The PSA inhibition value in the LNCaP sys-
tem (IC50 = 0.21 mM) was in agreement with the IC50 ( = 0.31 mM)
obtained from the AR eGFP assay, giving us confidence that
the developed chemical is a true AR inhibitor. Compound 23
also turned out to be more effective in reducing PSA levels in
enzalutamide-resistant MR49F cells (IC50 = 6.02 mM).
It should be noted that compound 23 is a close analog of com-
pound 1, which itself is the synthetic derivative of a previously
reported crystal ligand (17W of 4HLW (Munuganti et al., 2013)).
Therefore, we expanded its classification as the BF3-binder
based on structural similarity. Moreover, BLI experiments
confirmed that compound 23 directly binds to the AR LBD in
1:1 proportion, even at higher concentrations (Figure 3B), sug-
gesting single-site binding. Results from the androgen and
peptide displacement assays (Figure S1) rule out compound
23’s ability to interact at the androgen binding site and the AF2
pocket. Finally, the BF3-specific mechanism of compound 23
was confirmed with a fluorescence polarization assay where
the GARRPR portion of the Bag-1L protein (Jehle et al., 2014)
was used as a native BF3 ligand and was displaced by the com-
pound in a concentration-dependent manner (IC50 = 6. 10 mM;
Figure 4A). Because the AR BF3 site is a recently established
coactivator pocket (Este´banez-Perpin˜a´ et al., 2007), so far only
two proteins (FKBP52 and Bag-1L) have been reported to
interact with it. The IC50 observed for compound 23 in the
Bag-1L peptide displacement assay is higher than its cellular
activity (6.10 mM versus 0.31 mM). It should be noted that this
was observed in a cell-free assay. In reality, the BF3 site may
accommodate a variety of proteins, many of which could
contribute to or influence the cellular inhibitory activity of
compound 23. Further studies are underway to determine the
complete repertoire of interactions that can be blocked by the
BF3 inhibitors.
Figure 4B demonstrates that compound 23 possesses a
strong antiproliferative response on AR-dependent LNCaP and
MR49F cells (IC50 of 0.71 and 6.02 mM), whereas there was no
effect observed on AR-negative PC3 PCa cells. It should also
be noted that LNCaP cells contain a mutated AR-T877A form
of the receptor, whereas MR49F cells contain an AR with the
recently reported mutation F876L that can turn enzalutamide
into an agonist (Balbas et al., 2013). Because compound 23 isElsevier Ltd All rights reserved
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would not affect its efficacy. As expected, it retained activity
against both LNCaP and MR49F cells in all assays performed.
Chemogenomic investigation of the effects of compound 23
on gene expression in LNCaP cells revealed a decrease in the
expression of PSA and TMPRSS2 to levels comparable with
those seen after enzalutamide treatment (Figure 5A). Although
both compound 23 and enzalutamide reduced the expression
of a common set of AR target genes and demonstrated effective
inhibition of AR transcriptional activity, some genes were only
affected by one of the two compounds (Figure 5B), which could
likely be attributed to their different sites and modes of action on
the AR. A comprehensive bioinformatics analysis of the estab-
lished gene expression profiles of BF3 inhibitors is currently un-
der way. Recently, Ellinger-Ziegelbauer et al. (2009) published
a gene set that responds to cytotoxic drugs such as cisplatin
and paclitaxel. When we performed the same mRNA gene
expression analysis, compound 23 did not induce any of the
known genotoxic responses associated with this gene set, indi-
cating a different mechanism for decreasing cell viability.
Our in vivo studies demonstrated that compound 23 achieves
serum levels well above its IC50 and has a significant effect on
tumor growth as well as serum PSA levels in the LNCaP xeno-
graft model. However, the inhibition of serum PSA was minimal
compared with the impact on tumor volume. This is likely
because PSA production occurs independently of the cell
growth rate and may be influenced by various other factors,
including by the hormonal and stromal milieu (Gleave et al.,
1992). Upon testing the efficacy of compound 23 in the MR49F
enzalutamide-resistant xenograft model, a substantial inhibitory
effect on the volume was observed compared with the vehicle
control but with no significant effect on serum PSA levels (data
not shown). The difference in the efficacy of compound 23
between LNCaP and MR49F tumor xenograft models might be
due to mechanisms responsible for enzalutamide resistance in
MR49F cells, for example, expression of splice variants and/or
factors not necessarily related to the AR.
In this study, we report that an AR BF3 inhibitor, compound
23, exhibits very potent AR inhibition in androgen-sensitive and
enzalutamide-resistant cells in vitro and in vivo. Despite the
success of enzalutamide as the new standard hormone therapy
for advanced-stage PCa (Scher et al., 2012), sustained treatment
and response with this agent is limited by acquired resistance,
which typically develops within 6–12 months. In this context,
treatment with AR BF3-based drugs could potentially provide
another line of treatment and, thereby, enhance patient survival
and slow disease progression.
SIGNIFICANCE
The AR is an intensively studied therapeutic target impli-
cated in the development and progression of PCa. All clini-
cally used antiandrogens target the hormone binding pocket
of the receptor, which is prone to mutations that hampers
drug efficacy (Balbas et al., 2013). To address this problem,
we developed potent drug prototypes that target an alterna-
tive coactivator binding pocket (the BF3 site) of the AR and
effectively inhibit its transcriptional activity. Our findings
provide significant advances in identifying a chemical seriesChemistry & Biology 21, 1476–148that has an excellent activity profile both in vitro and in vivo.
Because our lead compound 23 has the potency and charac-
teristics to become an alternative therapeutic agent to treat
antiandrogen resistant forms of PCa, we will perform further
lead optimization and develop other derivatives suitable for
preclinical evaluation. It is anticipated that these AR inhi-
bitors will provide an alternative therapeutic strategy that
can be applied concurrently or simultaneously with current
antiandrogen treatments for PCa patients with advanced
disease.
EXPERIMENTAL PROCEDURES
In Silico Modeling
Instant JChem, a 2D similarity search tool from ChemAxon, was used to
search through the ZINC database (18 million compounds) for structural
analogs of 2-[(2-phenylethyl)sulfanyl]-1H-1,3-benzodiazole (compound 1).
A total of 295 compounds that generated Tanimoto coefficients >0.7 with
respect to the query structure were selected for further studies. Two docking
programs, Glide SP (Friesner et al., 2004) and eHiTs (Zsoldos et al., 2007) were
used for molecular docking. A crystal structure of AR (PDB ID code 4HLW;
Munuganti et al., 2013) from the Protein Data Bank (Berman et al., 2000)
was prepared for docking using the Maestro suite.
In Vitro Studies by Cell-Based and Biochemical Assays
Cell Culture
LNCaP and PC3 human PCa cells were obtained from the American Type
Culture Collection and grown in RPMI 1640 medium supplemented with 5%
fetal bovine serum (FBS) (Invitrogen). LNCaP and PC3 cells were tested and
authenticated by Idexx Radil (case no. 14616-2011) in June 2011. The LNCaP
eGFP cells (Tavassoli et al., 2007) were grown in phenol-red-free RPMI 1640
medium supplemented with 5% charcoal-stripped serum. HeLa-AR cells sta-
bly expressing the wild-type AR were grown in Dulbecco’s modified Eagle’s
medium supplemented with 5% FBS. Enzalutamide-resistant LNCaP cells
were provided by Dr. Zoubeidi (Kuruma et al., 2013) and were cultured in
RPMI 1640medium supplementedwith 5%FBS and 10 mMMDV3100. All cells
were maintained at 37C in 5% CO2.
eGFP Cellular AR Transcription Assay and PSA Assay
The inhibition effect of compounds was assessed as described previously
(Axerio-Cilies et al., 2011; Munuganti et al., 2013).
BLI Assay
The direct reversible interaction between small molecules and the AR was
measured as previously described (Axerio-Cilies et al., 2011).
Androgen Displacement Assay
Androgen displacement was assessed with a Polar Screen Androgen Recep-
tor Competitor Green assay kit (Invitrogen) according to the instructions of
the manufacturer.
SRC2-3 Peptide Displacement Assay
AR AF2-specific peptide displacement was assayed as described previously
(Axerio-Cilies et al., 2011).
Cell Viability Assay
See Supplemental Experimental Procedures.
Gene Expression Analysis
See Supplemental Experimental Procedures.
In Vivo Studies of Maximum Tolerable Dose and Pharmacokinetics
All animal experiments were conducted in accordance with the University of
British Columbia Committee on Animal Care. For the maximum tolerable
dose and serum level evaluation, 27 6- to 8-week-old athymic nude mice
(Harlan Sprague Dawley) were intravenously, intraperitoneally, or orally admin-
istered 50, 100, or 200 mg/kg of compound 23 solution formulated using 1:10
hydroxypropyl-cyclodextrin:double-distilled H2O. Mice were monitored for
24 hr for signs of acute toxicity, including death, lethargy, blindness, and
disorientation. To measure serum drug levels, tail blood samples were taken
from mice (100 mg/kg, n = 3) following the administration at time points
corresponding to 0, 0.5, 1, 2, 4, 6, 8, and 24 hr. Serum was separated by5, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1483
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liquid chromatography-mass spectrometry (LC-MS).
Assessment of In Vivo Tumor Growth for Castration-Resistant
LNCaP Xenografts and Enzalutamide-Resistant MR49F
Xenograft Transplantation
LNCaP
Six- to eight-week-old nude mice (Harlan Sprague Dawley) weighing 25–31 g
were subcutaneously inoculated with LNCaP cells (106 cells in BDMatrigel, BD
Biosciences) at a posterior dorsal site. Tumor volume, body weight, and serum
PSA levels weremeasuredweekly.When serumPSA levels reachedmore than
25 ng/ml, mice were castrated. When PSA recovered to precastration levels,
mice were randomized into three treatment groups (vehicle, 10 mg/kg of enza-
lutamide, or 200 mg/kg of Compound 23) and treated orally twice daily for
3 weeks. Calipers were used to measure the three perpendicular axes of
each tumor. The formula
V= ðL3W3HÞp
6
;
where L is the length, W the width, and H the height, was used to calculate the
tumor volume.Mice were also weighed weekly andmonitored daily for signs of
toxicity, including death, lethargy, blindness, and disorientation.
MR49F Cells
LNCaP-derived MR49F cells were excised and transplanted into castrated
mice treated with 10 mg/ kg of enzalutamide daily. When tumors reached
100–150 mm3, the enzalutamide treatment was stopped, and mice were
randomized into three treatment groups (vehicle, 10 mg/kg of enzalutamide,
or 200 mg/kg of compound 23) and treated orally twice daily for 3 weeks.
Serum Extraction and LC-MS Analysis
Serum samples generated from the in vivo studies were thawed, and 8 ml was
transferred to individual Eppendorf tubes. The internal standard (IS) of 2 ml of
0.5 mg/ml deuterated testosterone (d3T, C/D/N isotopes) was then added,
followed by 22 ml of acetonitrile, after which samples were vortexed for 5–
10 s and centrifuged for 5 min at 20,000 3 g to sediment precipitated protein.
The clarified supernatant was transferred to LC vials for analysis. Standards
were prepared in a similar fashion using blankmouse serum and also in parallel
using 50% methanol as a sample matrix to characterize any matrix effects.
Optima grade (Fisher Scientific) solvents and 18 MU water (Millipore) were
used for sample preparation and subsequent LC-MS analysis.
Analysis was carried out using an Acquity ultraperformace LC coupled in
series with an eLambda PDA (photodiode array) and a Quattro Premier
(Waters) MS detector. A 100 mm BEH C18, 1.7 m column (Waters) was
used to achieve separations with a 10%–95% acetonitrile (ACN) gradient
from 0.1–7 min (0.3 ml/min), followed by a 1 min 95% ACN flush (0.5 ml/min)
and a 2 min re-equilibration for a 10 min run length (0.1% formic acid present
throughout). Wavelengths detected between 210–800 nm at 1.2 nm resolu-
tion and 2 points/s were collected using the PDA. Extracted chromatograms
of 275 nm were used for compound 23 detection by PDA. All MS data were
collected in ES+ at unit resolution with the following instrument parameters:
capillary, 3.5 kV; extractor and radio frequency lens, 5 and 0.1 V, respec-
tively; source and desolvation temperatures, 120C and 350C, respectively;
desolvation and cone (N2) flow, 900 and 50 l/hr, respectively; collision gas
(Ar) flow, 0.15 ml/min (7.3 3 103 mbar). Compound 23 was detected
using multiple reaction monitoring (MRM) with m/z 235 > 118 and 235 >
142 for compound 23 and m/z 292 > 97 for d3T (25 V/20 V, 25 V/20 V,
and 32 V/21 V cone/collision volt combinations, respectively) with 0.1 s dwell
each. Retention times (RT) for compound 23 and d3T were 3.8 min and
4.8 min, respectively (Figure S8).
A comparison of scan data from treated versus untreated mouse serum led
to the identification of five metabolites that, based on their m/z, suggest that
they are hydroxyl and glucuronide products of the parent compound. These
metabolites were also measured using MRMs, with both of the hydroxyls
using m/z 251 > 91 (30 V/22 V cone/collision) and RT 2.5 and 2.75 min. Those
of the glucuronides werem/z 427 > 118, m/z 411 > 118, and 411 > 130 (35 V/25
V, 35 V/30 V, 35 V/25 V) and RT 2.2 min, 2.85 min, and 3.99 min, respectively.
Quantitation of metabolites was carried out against compound 23 assuming
an approximately equivalent response.1484 Chemistry & Biology 21, 1476–1485, November 20, 2014 ª2014Quanlynx (Waters) software was used for data analysis with external calibra-
tion for PDA data and IS-normalized calibration for MS data. Calibration
standards ranged from 0.01–40 mM (8 points, serum equivalent level) with
R2 > 0.99 and all percent deviation from nominal < 15% for MS data except
for the highest and lowest levels (highest level saturated, therefore omitted).
The usable range for optical density was 0.1–10 mM neat and 2.5–10 mM in
serum (<15% deviation), and an endpoint was used above 4 mM. Precision
and accuracy (n = 6) at 0.01, 0.1, and 1 mg/ml were within 15%. Comparisons
of pre- and postspiked serum with neat standards indicated a suppression
of about 10% and extraction efficiencies of 95%. Any samples out of the
calibration range were diluted 10-fold for reanalysis.
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